Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2015
Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutationsZhijie Wang, Zhirong Shen, Zhenxiang Li, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 1, 2022
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinomaZhihao Lu, Silu Yang, Xuerui Luo, et al.Oncotarget|October 6, 2017
Aldehyde dehydrogenase 1A1 increases NADH levels and promotes tumor growth via glutathione/dihydrolipoic acid-dependent NAD+ reductionBaiyun Wang, Xue Chen, Zixi Wang, et al.Cancer Letters|October 23, 2018
Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancerZhijie Wang, Shuai Fu, Jun Zhao, et al.Molecular Cell|February 2, 2019
Pacer Is a Mediator of mTORC1 and GSK3-TIP60 Signaling in Regulation of Autophagosome Maturation and Lipid MetabolismXiawei Cheng, Xiuling Ma, Qi Zhu, et al.Scientific Reports|June 23, 2015
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutationsZhijie Wang, Zhenxiang Li, Xiaosheng Ding, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 15, 2025
Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With TislelizumabMarkus Moehler, Harry H Yoon, Daniel-Christoph Wagner, et al.Biomarker Research|March 6, 2023
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumorsDingwei Ye, Jayesh Desai, Jingwen Shi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 TrialZhihao Lu, Wenting Du, Xi Jiao, et al.Nature|February 28, 2014
Is SIRT2 required for necroptosis?Kim Newton, Joanne M Hildebrand, Zhirong Shen, et al.Pageof 4